CNMD, US2074101013

CONMED stock rises to EUR 42.50, up 5.91 percent on NYSE

Published on 10/15/2026 at 19:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 343.49 million. CONMED stock costs EUR 42.50 on October 15, 2026 at 7:51 p.m. CEST, up 5.91 percent on the NYSE.

Market move and earnings date

The NYSE session on October 15, 2026 was the central market event for CONMED.
Second-quarter revenue reached USD 343.49 million.
CONMED stock costs EUR 42.50 at Lang & Schwarz on October 15, 2026 at 7:51 p.m. CEST, up 5.91 percent on the NYSE.
Third-quarter results are scheduled for October 28, 2026.

CNMD, US2074101013, Illustration mit AI erstellt.

CONMED stock (ISIN US2074101013) rose 5.91 percent on the NYSE on October 15, 2026, giving the medical-device company one of its strongest recent market sessions. The euro quote reached EUR 42.50 at Lang & Schwarz at 7:51 p.m. CEST, placing the German trading indication in the after-hours phase.

Second-quarter revenue sets the base

CONMED generated USD 343.49 million in revenue in the second quarter of 2026, while diluted earnings per share came to USD 0.77. Operating margin was 11.00 percent for the period, and operating cash flow reached USD 37.10 million.

The company had reported those second-quarter figures on July 29, 2026. MarketBeat said revenue exceeded the USD 337.60 million consensus estimate, while earnings per share beat the USD 1.11 estimate with USD 1.38 in the reported quarter. The same report listed full-year 2026 adjusted earnings-per-share guidance of USD 4.48 to USD 4.60.

Range leaves room below the high

CONMED traded between USD 44.89 and USD 47.76 on the NYSE on October 15, 2026, with volume of 142,738 shares against an average of 421,134. Its 52-week range was USD 31.44 to USD 53.66 as of October 9, 2026, leaving the stock 11.56 percent below the upper end.

The company had a market capitalization of USD 1.4 billion and a price-to-earnings ratio of 25.71 on October 15, 2026. The trailing dividend yield was 0.00 percent. MarketBeat listed a consensus third-quarter 2026 estimate of USD 1.00 in earnings per share and USD 336.28 million in revenue, compared with USD 1.08 and USD 337.93 million in the prior-year quarter.

Results date is October 28

CONMED announced on October 1, 2026 that it will publish third-quarter results after the market close on October 28, 2026. The conference call is scheduled for 4:30 p.m. ET. This date is the next concrete calendar point for the stock.

Comparison with peers

CONMED (NYSE, USD): plus 5.91 percent, price-to-earnings ratio 25.71, market capitalization USD 1.4 billion.

Stryker (NYSE, USD): plus 3.89 percent, price-to-earnings ratio 30.32, market capitalization USD 112.2 billion.

Integer Holdings (NYSE, USD): plus 0.10 percent, price-to-earnings ratio 34.63, market capitalization USD 4.3 billion.

After-hours price stays in focus

CONMED stock was trading at EUR 42.50 at Lang & Schwarz on October 15, 2026 at 7:51 p.m. CEST, up 5.91 percent on the NYSE. The next scheduled company event is the third-quarter report on October 28, 2026.

The further course of trading is shown by the continuously updated real-time quote of CONMED stock.